Skip to main content
Fig. 1 | The Journal of Headache and Pain

Fig. 1

From: Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials

Fig. 1

Change from pre-DBTP in monthly days of any acute headache medication, MSM, or non-MSM use. The change from pre-DBTP in monthly days of any acute headache medication, MSM, or non-MSM use at (A) mean over Months 4, 5, and 6 (EM) and (B) Month 3 (CM) is shown. Baseline values are mean ± SD; change from baseline values are adjusted analysis utilizing a generalized linear mixed model which includes treatment, visit, treatment by visit interaction, stratification factors and baseline value as covariates and assuming a first-order autoregressive covariance structure. DBTP, double-blind treatment phase; MSM, migraine-specific medication; non-MSM, non-migraine-specific medication, NS, non-significant; SD, standard deviation

Back to article page